Form 4: Hims & Hers CLO Sells Shares Under 10b5-1 Plan

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 2,637 shares of Class A Common Stock for $50.5 per share under a pre-arranged trading plan.

Summary

• Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported a sale of company stock.
• The transaction involved the disposition of 2,637 shares of Class A Common Stock.
• The shares were sold at a price of $50.5 per share.
• The sale occurred on September 17, 2025.
• Following this transaction, Soleil Boughton beneficially owns 166,404 shares of Class A Common Stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person on August 28, 2024.

Sentiment

Score: 5

Explanation: The sale was conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a planned diversification or liquidity event rather than a reaction to new material non-public information, thus having a neutral immediate sentiment.

Negatives

• While executed under a pre-arranged plan, any insider selling can sometimes be perceived by the market as a lack of confidence, though this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction under a pre-arranged trading plan and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may note the insider selling activity, though the pre-arranged nature of the 10b5-1 plan generally mitigates concerns about management's view of the company's immediate prospects.

Key Dates

Recommendation

The sale by the Chief Legal Officer was executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to manage personal finances and diversify holdings. This type of transaction is generally not considered a strong indicator of future company performance or a reason to alter an investment thesis, hence a 'hold' recommendation.

Keywords

Hims & Hers Health, HIMS, Insider Trading, Form 4, Stock Sale, Soleil Boughton, Chief Legal Officer, 10b5-1 Plan